Acumen Pharmaceuticals, Inc. ABOS

2.24 0.00 0.00% as of 25 Sep
Market cap
$161.6M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
— — — — — 0.00 0.00 —
P/S ratio
— — — — — 6.05 6.05 —
P/FCF ratio
— — — — — 0.00 0.00 —
P/Operating CF
— — — — — (2.04) (2.04) —
P/B ratio
— — — — — 0.00 0.00 —
Price to Tangible BV
— — — — — 0.00 0.00 —
EV/Sales
— — — — — (41.87) (41.87) —
EV/EBITDA
— — — — — 5.43 5.43 —
EV/Operating CF
— — — — — 5.58 5.58 —
EV/FCF
— — — — — 5.58 5.58 —
Quick Ratio
3.89 6.21 18.77 22.73 37.74 46.00 8.60 —
Current Ratio
4.07 6.46 19.01 23.08 38.60 46.57 9.38 —
Net Debt/EBITDA
0.69 1.20 3.33 3.98 10.00 5.53 0.84 —
Debt/Assets
25.37% 12.31% 9.64% 0.05% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.44 0.16 0.11 0.00 0.00 0.00 0.00 —
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.06 0.46 —
Operating CF/Net income
0.95 0.84 0.82 0.82 0.18 1.02 0.89 —
Capex/Depreciation
0.14 0.00 0.01 (0.25) (0.25) — — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(96.20%) (45.60%) (22.98%) (20.71%) (97.40%) 48.82% 51.22% —
ROA
(67.07%) (37.27%) (20.67%) (20.08%) (73.23%) (28.31%) (209.94%) —
ROIC
0.00% (179.60%) (71.63%) (250.76%) (39.55%) 0.00% 0.00% —
Return on Tangible Assets
(131.54%) (67.90%) (22.40%) (24.82%) (51.98%) (16.85%) (119.85%) —
Average Days of Receivables
— — — — — 27.71 6.45 —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 556.89% 505.36% —
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 94.08% 54.57% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 10.72% 10.25% —
Graham Net Nets
— — — — — (12.49) (12.49) —
Graham Number
— — — — — 132.11 0.00 —
Earnings Yield
— — — — — (1,065.13%) (1,065.13%) —
Free Cash Flow Yield
— — — — — (124.08%) (124.08%) —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 3.43 3.94 —
Operating CF per Share
(1.91) (1.44) (0.89) (0.87) (0.90) (17.78) (15.83) —
Capex per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Free Cash Flow per Share
(1.91) (1.44) (0.89) (0.87) (0.90) (17.78) (15.83) —
Cash per Share
1.93 2.86 5.01 4.37 9.68 104.48 15.21 —
Shareholders Equity per Share
1.16 3.03 5.49 4.65 11.23 (44.37) (26.51) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
1.16 3.03 5.49 4.65 11.23 (44.37) (26.51) —
Free Cash Flow
(115.63) (86.23) (43.08) (35.31) (18.00) (7.45) (6.82) —
Working Capital
92.25 150.70 233.64 172.52 193.51 43.48 6.41 —
Capital Expenditures
(0.09) (0.02) (0.02) (0.16) (0.04) — — —
Net Current Asset Value
69.85 121.13 203.46 172.52 193.51 (18.59) (11.56) —
EV/EBIT
— — — — — 5.43 5.43 —
Capex to Sales
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Net Profit Margin
0.00% 0.00% 0.00% 0.00% 0.00% (510.10%) (452.92%) —
Price to Operating Income
— — — — — 0.00 0.00 —
Other line items
Depreciation/Fixed assets
0.00 0.00 (24.07) 3.98 4.42 — — —
Cash ROIC
(52.89%) (22.52%) (7.99%) (9.64%) (4.29%) (29.58%) 140.06% —
Accounts Receivable Turnover
— — — — — 20.66 24.42 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Inventory Turnover
— — — 0.00 0.00 — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Days of Inventory on Hand
— — — 0.00 0.00 — — —
Average Receivables
— — — — — 0.07 0.07 —
Average Payables
3.10 3.51 1.51 1.36 0.81 0.38 0.38 —
Average Assets
180.91 274.56 253.36 213.46 137.38 25.88 3.66 —
Average Common Equity
126.12 224.39 227.87 206.98 103.30 (15.01) (15.01) —

Fold the line items

Columns are period end dates